Table 1.
Clinical characteristics of MuSK MG patients at the time of blood draw (N=11; all were female)
| Age (Yr) | Race | Disease Duration (Mo) | Maximum MGFA Severity Class | MG-MMT | MGFA-PIS | Thymectomy | Immunosuppressives |
|---|---|---|---|---|---|---|---|
| 22 | B | 13 | V | 16 | I | Yes | Prednisone 10mg/d; AZA 100mg/d; monthly TPE |
| 47 | W | 144 | IIIB | 1 | MM | Yes | MMF 750mg/d; RTX 22 months prior to blood draw |
| 59 | B | 180 | IIIB | 2 | MM | No | Prednisone 20mg QOD; MMF 2g/d |
| 22 | B | 144 | V | 7 | I | Yes | MMF 1.5g/d |
| 45 | B | 14 | I | 3 | U | No | Prednisone 17.5mg/d |
| 66 | W | 216 | IIIB | 3 | MM | No | MMF 2g/d |
| 55 | W | 165 | IIIB | 2 | MM | Yes | RTX 13 months prior to blood draw |
| 28 | B | 105 | IIIB | 0 | CSR | Yes | None |
| 64 | W | 139 | V | 3 | MM | Yes | Prednisone 2.5mg QOD; MMF 4g/d |
| 19 | B | 21.5 | IVB | 28 | I | No | MMF 1g/d d/c 11 days prior to blood draw; TPE 11 days prior to blood draw; prednisone 20mg/d |
| 62 | W | 135 | V | 23 | I | No | AZA 150mg/d; prednisone 5mg/d; RTX 3 years prior to blood draw |
Abbreviations: AZA=azathioprine; B=black; BID=twice daily; CSR=complete stable remission; d=day; d/c=discontinued; F=female; g=grams; I=improved; MGFA=Myasthenia Gravis Foundation of America; MM=minimal manifestations; MMF=mycophenolate mofetil; MG-MMT=myasthenia gravis manual muscle testing score at time of blood draw; Mo=months; PIS=post intervention status at time of blood draw; QOD=every other day; RTX=rituximab; TPE=therapeutic plasma exchange; U=unchanged; W=white; Yr=years